msa-alpha-synuclein-glial-cytoplasmic-inclusions

MSA Alpha-Synuclein Glial Cytoplasmic Inclusions

Overview

Glial cytoplasmic inclusions (GCIs) represent the defining pathological hallmark of Multiple System Atrophy (MSA), distinguishing it from other α-synucleinopathies like Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB). Unlike PD/DLB where α-synuclein aggregates primarily in neurons, MSA features predominant α-synuclein pathology in oligodendrocytes—the myelin-producing cells that support axons in the central nervous system. This oligodendroglial α-synucleinopathy underlies the rapidly progressive nature of MSA and its poor therapeutic response. [@pr漫步2022][@aoki2023]

GCI Pathogenesis

GCI Formation Mechanism

GCIs are silver-positive, eosinophilic inclusions composed primarily of aggregated α-synuclein filaments co-assembled with phosphorylated α-synuclein, tau, and other neurodegenerative-associated proteins including p25α (TPPP/p25α), a brain-specific phosphoprotein enriched in oligodendrocytes. The sequential model of GCI formation involves:

MSA Alpha-Synuclein Glial Cytoplasmic Inclusions

Overview

Glial cytoplasmic inclusions (GCIs) represent the defining pathological hallmark of Multiple System Atrophy (MSA), distinguishing it from other α-synucleinopathies like Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB). Unlike PD/DLB where α-synuclein aggregates primarily in neurons, MSA features predominant α-synuclein pathology in oligodendrocytes—the myelin-producing cells that support axons in the central nervous system. This oligodendroglial α-synucleinopathy underlies the rapidly progressive nature of MSA and its poor therapeutic response. [@pr漫步2022][@aoki2023]

GCI Pathogenesis

GCI Formation Mechanism

GCIs are silver-positive, eosinophilic inclusions composed primarily of aggregated α-synuclein filaments co-assembled with phosphorylated α-synuclein, tau, and other neurodegenerative-associated proteins including p25α (TPPP/p25α), a brain-specific phosphoprotein enriched in oligodendrocytes. The sequential model of GCI formation involves:

Oligodendrocyte-Specific Factors

The targeting of oligodendrocytes rather than neurons in MSA reflects several oligodendrocyte-specific factors:

| Factor | Role in GCI Pathogenesis | Reference |
|--------|------------------------|-----------|
| p25α/TPPP | Key GCI component; regulates microtubule dynamics | [@aoki2023] |
| MBP | Myelin Basic Protein; recruited to GCIs | [@martens2022] |
| PLP1 | Proteolipid Protein 1; lipid metabolism | [@martens2022] |
| CNP | 2',3'-Cyclic Nucleotide 3'-Phosphodiesterase | [@valera2021] |
| MAG | Myelin-Associated Glycoprotein | [@valera2021] |

SNCA Gene Dysregulation in MSA

SNCA Multiplication

While SNCA point mutations cause familial PD, duplications and triplications of the SNCA gene have been linked to MSA cases, supporting a dose-dependent relationship between α-synuclein expression and oligodendrocyte pathology. [@kiyosawa2019] Studies show:

• SNCA duplication carriers: Develop MSA phenotype with prominent GCI pathology
• SNCA triplication carriers: Earlier onset and more severe disease
• SNCA expression in oligodendrocytes: Driven by oligodendrocyte-specific promoters (PLP1, MBP)

Transcriptional Dysregulation

Multiple mechanisms drive SNCA overexpression in MSA oligodendrocytes:

Regional Vulnerability Patterns

MSA demonstrates selective vulnerability in specific brain regions, correlating with clinical subtypes:

Striatonigral degeneration (MSA-P)

• Affected regions: Putamen, caudate, substantia nigra pars compacta
• Pathology: Severe GCI burden, neuronal loss, iron deposition
• Clinical correlation: Parkinsonian features (bradykinesia, rigidity)
• Mechanism: Dopaminergic neuron loss secondary to oligodendrocyte failure

Olivopontocerebellar degeneration (MSA-C)

• Affected regions: Inferior olive, pons, cerebellar white matter
• Pathology: GCI-mediated demyelination, Purkinje cell loss
• Clinical correlation: Cerebellar ataxia, gait disturbance
• Mechanism: Disruption of olivocerebellar projections

Autonomic Centers

• Affected regions: Nucleus tractus solitarius, dorsal motor nucleus of vagus, Onuf's nucleus
• Pathology: Variable GCI burden with neuronal loss
• Clinical correlation: Orthostatic hypotension, urinary dysfunction, erectile dysfunction
• Mechanism: Autonomic regulatory center dysfunction

Co-Pathology Patterns

α-Syn/Tau Co-Aggregation

A subset of MSA cases show co-pathology with tau protein, particularly in regions with high GCI burden:

• Mixed pathology: 20-30% of MSA cases show significant tau pathology
• Tau isoforms: Predominantly 4-repeat tau (4R-tau)
• Pattern: Tau-positive inclusions in neurons adjacent to GCI-rich regions
• Clinical impact: May accelerate disease progression

LRRK2 Co-Occurrence

• LRRK2 G2019S carriers: May develop MSA phenotype
• Pathological features: Typical GCI pathology with LRRK2 positivity
• Implication: LRK2 inhibitors may have therapeutic potential

Therapeutic Approaches

α-Synuclein Targeting

Multiple strategies targeting α-synuclein aggregation are in development:

| Approach | Stage | Mechanism | Reference |
|----------|-------|-----------|------------|
| Immunotherapy (ABBV-080) | Phase 1/2 | Anti-α-syn antibodies | [@song2024] |
| Small molecule aggregation inhibitors | Preclinical | Block oligomerization | [@song2024] |
| Gene therapy (SNCA silencing) | Preclinical | RNAi/ASO | [@song2024] |

cAMP-Based Therapeutic Targeting

Oligodendrocyte function depends critically on cAMP signaling:

• Phosphodiesterase inhibitors: Increase cAMP to support oligodendrocyte survival
• Adenylyl cyclase agonists: Activate cAMP pathway
• Rolipram: PDE4 inhibitor showing preclinical promise

Clinical Trials

| Trial | Intervention | Phase | Status |
|-------|--------------|------|--------|
| NCT03533038 | Saroglitazar | Phase 2 | Completed |
| NCT04182885 | ABBV-080 | Phase 1 | Active |
| NCT04269642 | CoQ10 | Phase 3 | Recruiting |
| NCT04065014 | Rifampin | Phase 2 | Completed |

Neurotrophic Factors

• GDNF delivery: AAV-GDNF in preclinical models
• BDNF: Supporting oligodendrocyte survival
• MBP rescue agents: Targeting myelin maintenance

Cross-Links

• [Multiple System Atrophy Pathway](/mechanisms/multiple-system-atrophy-pathway)
• [Alpha-Synuclein Aggregation](/mechanisms/alpha-synuclein-aggregation)
• [Glial Cytoplasmic Inclusions (MSA overview)](/mechanisms/glial-cytoplasmic-inclusions-msa)
• [Parkinson's Disease](/diseases/parkinsons-disease)
• [Oligodendrocyte Dysfunction](/cell-types/oligodendrocytes)
• [SNCA Gene](/genes/snca)
• [TREM2 Microglia Pathway](/mechanisms/trem2-microglia-pathway)

References